Acknowledgement for APICES collaboration in IMANOL study published in “Cancers”
This month, we want to share the acknowledgment that APICES has received in the recent publication titled “Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study”, published in Cancers in which APICES has collaborated in study design, setup, coordination and project management, monitoring, data management, pharmacovigilance, statistical analysis and manuscript writing.
This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank SOGUG and Dr María José Juan for giving us the opportunity to appear in the acknowledgements of the publication and congratulate them and all the investigators for their project success.
IMANOL trial evaluates the effect of maintenance treatment with olaparib on radiographic PFS in patients with mCRPC who had received previous treatment with docetaxel and achieved partial or complete response or disease stabilization and had a documented germline/somatic mutation in any of the homologous recombination repair genes.
You can find the publication in the following link: https://www.mdpi.com/2072-6694/15/21/5223
